She was 36 years old, held a doctorate in biomedical sciences, and had spent the better part of a decade trying to find a way to catch one of the deadliest cancers in women before it killed them. Now, she’s gone — and the scientific community, along with millions of online followers, is left grappling with the loss.
Stephanie Buttermore, a cancer research scientist, social media personality, and fiancée of fitness YouTuber Jeff Nippard, died suddenly at age 36 after a decade together as partners. Nippard’s team confirmed the news in a statement that was as brief as it was devastating: “It is with profound sorrow that we share the sudden passing of Jeff’s fiancée and partner of 10 years, Stephanie.” No further details about the cause of death have been made public.
A Scientist First
Before she was a fitness influencer with millions of subscribers, Buttermore was a researcher. A serious one. She earned her undergraduate degrees in Microbiology, Molecular Biology, and Medical Sciences — with a focus on women’s health — before completing her PhD in Biomedical Sciences, Pathology and Cell Biology at the University of South Florida. Her background wasn’t decorative. It was the foundation of work that genuinely mattered.
Her 2017 dissertation tackled something specific and urgent: the role of a protein called RHAMM — formally known as the Hyaluronan-Mediated Motility Receptor — in ovarian cancer. The research showed that RHAMM was overexpressed in clinical ovarian cancer specimens, and that silencing the protein inhibited cancer cell migration and invasion. In her own words, “Taken together, the studies described herein suggest that RHAMM contributes to OC and that further studies are warranted to further elucidate the clinical role of RHAMM in OC.” Measured, careful language — the way scientists speak when they know they’re onto something but won’t overreach.
Why Ovarian Cancer? Why This Protein?
Here’s the brutal arithmetic of ovarian cancer: when it’s caught early, survival rates exceed 90 percent. When it’s caught late — which it usually is, because there’s no reliable early screening method — that number collapses to under 30 percent. That gap is where thousands of women fall through every year, and it’s precisely the gap Buttermore was trying to close.
Her doctoral research found that RHAMM protein was upregulated not just in ovarian cancer cell lines and tissue, but also in patient urine — a detail that carries enormous practical weight. Urine-based screening is non-invasive, scalable, and cheap. A pilot study suggested RHAMM expression tracks with cancer progression, raising the possibility of using it as both an early detection marker and a prognostic tool. It’s the kind of finding that doesn’t make headlines but quietly moves the needle in oncology labs.
That’s the catch with academic research — it moves slowly, incrementally, and mostly out of public view. Buttermore seemed to understand that. Her YouTube channel described her explicitly as a cancer research scientist with a PhD in pathology and cell biology, focusing on the molecular mechanisms of ovarian cancer. She never seemed to want people to forget what she actually did for a living.
The Public Chapter
Still, it’s impossible to talk about Buttermore without acknowledging the other dimension of her public life — one that drew scrutiny, admiration, and genuine conversation about bodies, food, and mental health in equal measure. In recent years, she’d stepped back considerably from social media, and by her own account, the break had been transformative.
“My mental health has been the best it’s ever been, but I’ll give you some specifics,” she shared openly with her audience. “I no longer struggle with anxiety. At all.” It was a striking admission from someone who had built a platform on visibility — and a reminder that the people we follow online are navigating the same pressures the rest of us are, often more acutely.
What Remains
Grief, of course, is personal. But Buttermore’s death raises a quieter question worth sitting with: how many researchers like her — people doing painstaking, underfunded, unglamorous work on diseases that disproportionately kill women — never get a public platform at all? She had one, and she used it to talk about science, about her body, about anxiety, about what it means to be a woman navigating all of it at once.
Her dissertation on RHAMM and ovarian cancer sits in a digital archive, available to anyone who looks. The research is unfinished, as most research is. But it points somewhere — toward a urine test, toward an earlier diagnosis, toward the possibility that more women might one day hear the word “cancer” while there’s still time to fight it. That work doesn’t disappear with her.
Sometimes the most important things a person leaves behind are the questions they were still trying to answer.
